Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
We investigated the effect of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl), a marker compound isolated from the cortex of Magnolia officinalis, in non-obese type 2 diabetic Goto-Kakizaki (GK) rats. The rats were treated orally with magnolol (100 mg/kg body weight) once a day for 13 weeks. In magnolol-treated GK rats, fasting blood glucose and plasma insulin were significantly decreased, and the pancreatic islets also showed strong insulin antigen positivity. Urinary protein and creatinine clearance (Ccr) were significantly decreased. Pathological examination revealed the prevention of the glomeruli enlargement in magnolol-treated GK rats. The overproduction of renal sorbitol, advanced glycation endproducts (AGEs), type IV collagen, and TGF-beta1 mRNA were significantly reduced in magnolol-treated GK rats. Thus based on our findings, the use of magnolol could result in good blood glucose control and prevent or retard development of diabetic complications such as diabetic nephropathy.
Sohn
Eun Jin
EJ
Department of Herbal Pharmaceutical Development, Korea Institute of Oriental Medicine, 461-24 Jeonmin-dong, Yuseong-gu, Daejeon 305-811, Republic of Korea.
Kim
Chan-Sik
CS
Kim
Young Sook
YS
Jung
Dong Ho
DH
Jang
Dae Sik
DS
Lee
Yun Mi
YM
Kim
Jin Sook
JS
D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D024141:Collagen Type IV / Q000378:metabolism; D003404:Creatinine / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D007150:Immunohistochemistry; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism; D017705:Lignans / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D031566:Magnolia / Q000737:chemistry; D008297:Male; D024301:Plant Bark / Q000737:chemistry; D018517:Plant Roots / Q000737:chemistry; D011507:Proteinuria / Q000517:prevention & control; D051381:Rats; D011919:Rats, Inbred Strains; D013012:Sorbitol / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D001713:Biphenyl Compounds; D001786:Blood Glucose; D024141:Collagen Type IV; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D007328:Insulin; D017705:Lignans; D053773:Transforming Growth Factor beta1; C005498:magnolol; D013012:Sorbitol; D003404:Creatinine